The Food and Drug Administration approved a new type of drug that combines the widely used breast cancer medicine Herceptin with a powerful toxin to more effectively kill cancer cells while potentially reducing side effects. The drug, which will be called Kadcyla but was known as T-DM1 during its development, extended the median survival of women with advanced breast cancer by nearly half a year in a clinical trial. This drug has opened new doors for late stage breast cancer patients.
In addition, it is meaningful to me that when this drug was in the trial stages, as T-DM1, some of the patients in the trial were women fighting IBC. Thank you ladies for being willing to participate in research. Research saves lives.
For full article click here